HIV感染女性的原发HPV与分子宫颈癌筛查
本研究纳入865名HIV感染女性,评估原发HPV筛查(PHS)及其反射分流的效能。PHS对癌前病变灵敏度87%,阴道镜转诊率35%;联合HPV16/18分型可减少阴道镜转诊。PHS联合反射HPV16/18分型可能成为联合检测的替代方案。
要点
- PHS对癌前病变灵敏度87%,阴道镜转诊率35%。
- PHS联合反射HPV16/18分型及Pap灵敏度84%,阴道镜转诊率30%。
- PHS联合反射HPV16/18分型可减少不必要的阴道镜转诊。
核心结论
- PHS联合反射HPV16/18分型可减少不必要的阴道镜转诊,若经证实可能作为HIV感染女性联合检测的替代方案。
研究设计与样本
- 纳入865名HIV感染女性(323名来自WIHS队列,542名来自WIHS附属阴道镜门诊),均接受Pap和致癌HPV检测及HPV16/18分型。
主要发现
- PHS对癌前病变灵敏度87%,阳性预测值9%,阴道镜转诊率35%。
- PHS联合反射HPV16/18分型及Pap检测灵敏度84%,阳性预测值16%,阴道镜转诊率30%。
- PHS仅联合HPV16/18分型阴道镜转诊率24%。
- 联合检测灵敏度91%,阳性预测值12%,阴道镜转诊率40%。
关键数值与推荐
- PHS对癌前病变灵敏度87%(95%CI未报告),阳性预测值9%,阴道镜转诊率35%。
- PHS联合反射HPV16/18分型及Pap检测灵敏度84%,阳性预测值16%,阴道镜转诊率30%。
- 联合检测灵敏度91%,阳性预测值12%,阴道镜转诊率40%。
- p16/Ki-67免疫细胞化学阳性预测值20%,标本不足率13%。
临床怎么用
- 在HIV感染女性中可考虑采用PHS联合反射HPV16/18分型作为筛查策略,以减少不必要的阴道镜转诊。
局限性
- PHS在HIV感染女性中研究较少,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary human papillomavirus (HPV) screening (PHS) utilizes oncogenic human papillomavirus (oncHPV) testing as the initial cervical cancer screening method and typically, if positive, additional reflex-triage (eg, HPV16/18-genotyping, Pap testing). While US guidelines support PHS usage in the general population, PHS has been little studied in women living with HIV (WLWH). METHODS: We enrolled n = 865 WLWH (323 from the Women's Interagency HIV Study [WIHS] and 542 from WIHS-affiliated colposcopy clinics). All participants underwent Pap and oncHPV testing, including HPV16/18-genotyping. WIHS WLWH who tested oncHPV[+] or had cytologic atypical squamous cells of undetermined significance or worse (ASC-US+) underwent colposcopy, as did a random 21% of WLWH who were oncHPV[-]/Pap[-] (controls). Most participants additionally underwent p16/Ki-67 immunocytochemistry. RESULTS: Mean age was 46 years, median CD4 was 592 cells/µL, 95% used antiretroviral therapy. Seventy WLWH had histologically-determined cervical intraepithelial neoplasia grade 2 or greater (CIN-2+), of which 33 were defined as precancer (ie, [i] CIN-3+ or [ii] CIN-2 if concurrent with cytologic high grade squamous intraepithelial lesions [HSILs]). PHS had 87% sensitivity (Se) for precancer, 9% positive predictive value (PPV), and a 35% colposcopy referral rate (Colpo). "PHS with reflex HPV16/18-genotyping and Pap testing" had 84% Se, 16% PPV, 30% Colpo. PHS with only HPV16/18-genotyping had 24% Colpo. "Concurrent oncHPV and Pap Testing" (Co-Testing) had 91% Se, 12% PPV, 40% Colpo. p16/Ki-67 immunochemistry had the highest PPV, 20%, but 13% specimen inadequacy. CONCLUSIONS: PHS with reflex HPV16/18-genotyping had fewer unnecessary colposcopies and (if confirmed) could be a potential alternative to Co-Testing in WLWH.
引用
- Strickler HD, Keller MJ, Hessol NA, et al. Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021. PMID: 32881999. doi:10.1093/cid/ciaa1317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。